X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, Mankind Pharma will distribute AstraZeneca's anti-asthma inhaled corticosteroid drug Symbicort, (budesonide/formoterol) approved to treat asthma and COPD, in India.
Lead Product(s): Budesonide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Symbicort
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 13, 2024
Details:
The investment will support the development of the Actimed pipeline, including ACM-001.1 (S-pindolol benzoate), with preparations under way for a Phase 2b/3 programme targeted at the treatment of cancer cachexia in non-small cell lung cancer and colorectal cancer.
Lead Product(s): S-pindolol Benzoate
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Actimed Therapeutics
Deal Size: $6.3 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 26, 2023
Details:
ACM-001.1 (S-pindolol benzoate) targets multiple pathways that drive cachexia and has generated promising proof of concept Phase 2a clinical data in cachexia patients.
Lead Product(s): Pindolol
Therapeutic Area: Nutrition and Weight Loss Product Name: ACM-001.1
Highest Development Status: Phase IIProduct Type: Small molecule
Recipient: Actimed Therapeutics
Deal Size: $12.1 million Upfront Cash: Undisclosed
Deal Type: Financing January 04, 2023
Details:
The acquisition of “Combihale” is expected to strengthen Mankind’s presence in the inhalation respiratory market segment. Daffy is a soap-free moisturising bar for infant babies.
Lead Product(s): Formoterol Fumarate,Fluticasone Propionate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Combihale
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 16, 2022
Details:
The top selling brands are Pangraf (tacrolimus), Alphadol (alfacalcidol), Cilamin (penicillamine) & Livoluk Fibre (lactulose in combination with ispaghula) were ranked number 1, whereas Glizid (Gliclazide + Metformin), Mycept (Mycophenolate Mofetil) were among the top 5.
Lead Product(s): Tacrolimus
Therapeutic Area: Dermatology Product Name: Pangraf
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Panacea Biotec Limited
Deal Size: $251.1 million Upfront Cash: Undisclosed
Deal Type: Agreement February 01, 2022
Details:
Mankind pharma launched Molulife (Molnupiravir) developed by MSD and Ridgeback Biotherapeutics by next week, It is also expected that Cipla, Sun pharma, and DRL will also release Molnupiravir in the coming weeks for the treatment of patients with severe COVID19.
Lead Product(s): Molnupiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Molulife
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2022
Details:
Mankind Pharma has launched Justoza, a Dapagliflozin brand marketed by Mankind to treat diabetes, heart failure and chronic kidney disease. Launching API DMF grade dapagliflozin is an innovative futuristic approach to provide the best in class quality to the patients.
Lead Product(s): Dapagliflozin
Therapeutic Area: Endocrinology Product Name: Justoza
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2021
Details:
MKP10241, a new class of anti-diabetic molecules, is designed and developed at the Mankind Research Centre. It is a potent and orally administered small molecule, GPR119 agonist. GPR 119 is highly expressed in pancreatic beta cells and intestinal enteroendocrine cells.
Lead Product(s): MKP10241
Therapeutic Area: Endocrinology Product Name: MKP10241
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 19, 2021
Details:
Posaconazole has been found to be a safer and effective drug of choice for the management of the disease. The drug has received approval from the Drug Controller General of India (DCGI).
Lead Product(s): Posaconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
Company announced that new data from clinical studies of Afrezza® demostrating safe and effective dosing, its association with weight loss in patients with type 2 diabetes, and an evaluation of a comprehensive two year safety study showing that significant changes in FEV1.
Lead Product(s): Insulin
Therapeutic Area: Endocrinology Product Name: Afrezza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
